Bharat Biotech’s nasal vaccine for Covid-19 gets approved for ‘restricted use’ among ‘adults’

As India continues its fight against Covid-19, the very first intranasal vaccine manufactured by Bharat Biotech got approved by the Drugs Controller General of India (DCGI) on Tuesday. The vaccine has been approved for ‘restricted emergency use in those aged above 18 years’.

Hyderabad-based Bharat Biotech International Limited (BBIL), the maker of Covaxin completed clinical trials of the nasal vaccine with about 4,000 volunteers. No side effects or adverse reactions were reported, news agency PTI reported quoting company sources.

Taking to twitter Union Health Minister Mansukh Mandaviya shared the information on the new nasal vaccine. "With the science-driven approach & Sabka Prayas, we will defeat COVID-19," Mandaviya said.

Big Boost to India's Fight Against COVID-19!

Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.

— Dr Mansukh Mandaviya (@mansukhmandviya) September 6, 2022

In August, it said its COVID-19 intranasal vaccine was proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials phase -3.

In Feb this year, Mumbai-based Glenmark launched a nasal spray for adult patients in what was the country's first such anti-Covid drug, in partnership with SaNOtize.

With PTI Inputs

ALSO WATCH: WHO: New Covid cases, deaths keep falling nearly everywhere